selecting between autosct & car-t in dlbcl: patient selection, drug access, and long-term efficacy
Published 1 year ago • 69 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
1:04
bispecifics & car-t therapy in dlbcl: sequencing and selecting between these agents
-
0:49
treating dlbcl with car-t: the best candidates and selecting a car-t product
-
2:52
comparing the efficacy and curative potential of car-t therapy & bispecific antibodies in r/r dlbcl
-
2:05
strategies to implement car-t in dlbcl
-
1:33
patient selection for car-t in all
-
4:14
choosing the right car-t therapy for r/r dlbcl
-
2:53
autohct in dlbcl in the car-t era
-
2:25
healthcare decision-making in patients with dlbcl treated with car-t vs. non-car-t therapies
-
11:17
car-t cells: engineered cancer killers
-
8:46
today immunotherapy can cure even fourth stage cancer: dr dattatreyudu nori
-
3:09
car t-cell therapy: side effects
-
3:21
practical considerations for car-t therapy in lymphoma
-
3:21
safety management of car-t cell therapy in dlbcl
-
2:34
safety considerations in car-t therapy: patient selection and side effects
-
3:18
evaluating dual-targeting cd19/22 car-t cells in patients with r/r all
-
3:05
car-t therapy in r/r dlbcl
-
2:38
car t-cells improve response and cr rates in r/r dlbcl
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all
-
3:10
universal car-t therapy for t-all
-
2:42
clinical indications for car-t therapy in dlbcl & the possibility of moving car-t into earlier lines
-
1:28
assessment of car-t and tcr adverse events
-
1:15
the current status of car-t therapy in second-line dlbcl in europe